[{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Concert Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Deuruxolitinib phosphate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.

                          Brand Name : Leqselvi

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 26, 2024

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AG...

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : $15.0 million

                          December 05, 2023

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 06, 2023

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Der...

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : $576.0 million

                          March 06, 2023

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : $576.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 15, 2023

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in lat...

                          Brand Name : CTP‑543

                          Molecule Type : Small molecule

                          Upfront Cash : $576.0 million

                          January 19, 2023

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : $576.0 million

                          Deal Type : Acquisition

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 21, 2022

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp ...

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 10, 2022

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 22, 2022

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : A statistically significant proportion of patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 (deuterated ruxolitinib) experienced greater scalp regrowth compared to placebo.

                          Brand Name : CTP-543

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 01, 2022

                          Lead Product(s) : Deuruxolitinib phosphate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank